A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

计划入组 167 人 · 首次发布于 2025 年 3 月 3 日

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

计划入组 162 人 · 首次发布于 2022 年 6 月 13 日

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

计划入组 52 人 · 首次发布于 2021 年 5 月 21 日

TERN-501

TERN-301

TERN-800

TERNS, INC.

United States

TERNS PHARMACEUTICALS INC.

Cayman Islands

Teres Bio, Inc.

United States

Terns Pharmaceuticals' Oral GLP-1 Agonist TERN-601 Shows Promise in Phase 1 Obesity Trial

Terns Pharma's TERN-701 Shows Promise in Phase I CML Trial

Terns Pharmaceuticals Closes $747.5 Million Public Offering to Advance BCR-ABL Inhibitor TERN-701